Stivarga is owned by Bayer Hlthcare.
Stivarga contains Regorafenib.
Stivarga has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Stivarga are:
Stivarga was authorised for market use on 27 September, 2012.
Stivarga is available in tablet;oral dosage forms.
Stivarga can be used as treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kinase inhibitor.
The generics of Stivarga are possible to be released after 09 July, 2032.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7351834 | BAYER HLTHCARE | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jun, 2022
(8 months ago) | |
US8637553 | BAYER HLTHCARE | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
Feb, 2031
(7 years from now) | |
US9957232 | BAYER HLTHCARE | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate |
Jul, 2032
(9 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8680124 | BAYER HLTHCARE | Treatment of cancers with acquired resistance to kit inhibitors |
Jun, 2030
(7 years from now) | |
US9458107 | BAYER HLTHCARE | Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate |
Apr, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 27, 2024 |
Drugs and Companies using REGORAFENIB ingredient
Market Authorisation Date: 27 September, 2012
Treatment: Treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kinase inhibitor
Dosage: TABLET;ORAL
23
United States
11
European Union
6
Argentina
6
China
6
Japan
6
Australia
5
Brazil
5
Korea, Republic of
5
Canada
4
Malaysia
4
Spain
4
Costa Rica
4
New Zealand
4
Taiwan, Province of China
4
Hong Kong
4
Israel
3
Portugal
3
Singapore
3
Uruguay
3
Russia
3
Guatemala
3
Mexico
3
Morocco
3
Peru
3
Tunisia
3
Slovenia
3
Ukraine
3
Poland
3
Chile
3
Denmark
2
Jordan
2
Croatia
2
Colombia
2
Dominican Republic
2
Honduras
2
South Africa
2
Cyprus
2
Hungary
2
Cuba
2
Ecuador
1
Germany
1
El Salvador
1
Panama
1
Norway
1
EA
1
Luxembourg
1
ME
1
Yugoslavia
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic